GI INNO Presents 6 Immuno-Oncology Pipeline Projects at International Conference

Including AI Analysis Data

GI Innovation announced on the 30th that it will present six major immuno-oncology drug pipeline projects, including artificial intelligence (AI) analysis data, at the European Society for Medical Oncology (ESMO) and the Society for Immunotherapy of Cancer (SITC) in the United States.

GI Innovation logo. [Image provided by GI Innovation]

ESMO and SITC are considered two of the world's top four cancer conferences, along with the American Society of Clinical Oncology (ASCO), recognized as the most prominent in cancer research. ESMO will be held in Madrid, Spain, from October 20 to 24, and SITC will take place in San Diego, USA, from November 1 to 5.

GI Innovation will present two research results at ESMO and four at SITC. These research results include interim data from the immuno-oncology drug GI-101 as a monotherapy and in combination with MSD's Keytruda (Keynote-B59), as well as preclinical results of the next-generation immuno-oncology drug GI-102 and the metabolic immuno-oncology drug GI-108.

In particular, the company plans to reveal clinical analysis results of GI-101 using AI machine learning techniques. GI-101 has accumulated a vast amount of data, including anti-cancer active biomarkers and immune cells, through monotherapy and combination clinical trials with Keytruda. To identify which factors among this big data have the greatest impact on anti-cancer activity, the company utilized a survival analysis method called 'Random Survival Forest,' based on AI machine learning techniques. Through this, in collaboration with Professor Cha Dong-woo's team at Severance Hospital, it was found that the more effectively immune cells increase after GI-101 administration, the significantly longer the progression-free survival period.

Yoon Nari, Executive Director of Clinical Development, explained, "When AI analysis was conducted by inputting various information such as tumor size and patient response rate in the GI-101 clinical trial, the factor most strongly associated with the extension of progression-free survival after GI-101 administration was the increase in immune cells," adding, "The greater the increase in immune cells after GI-101 administration, the more the anti-cancer activity was observed to increase."

Additionally, at these two conferences, preclinical results of the subcutaneously injectable immuno-oncology drug GI-102, which GI Innovation is developing as a follow-up pipeline, and the fourth-generation immuno-oncology drug GI-108, currently in the preclinical stage, will also be disclosed.

Jang Myung-ho, Chief Clinical Officer, stated, "We are pleased that six poster presentations were accepted at ESMO and SITC, recognizing our company's research and development achievements in the international oncology community," and added, "Since global pharmaceutical companies are highly interested in GI-101 and GI-102, which can increase anti-cancer NK cells with significantly lower toxicity compared to competitors, we will do our best to achieve technology transfer at the early clinical stage."